Cerus Corp - Company Profile
Powered by 
All the sales intelligence you need on Cerus Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Cerus Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Cerus Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Cerus Corp (Cerus) is a biomedical products company focused on enhancing blood safety and preserving the therapeutic properties of platelets, plasma, and red blood cell, and IFC transfusion products. The company develops and commercializes the INTERCEPT Blood System, which is designed to reduce blood-borne pathogens such as HIV, West Nile, SARS, hepatitis B and C, bacteria, parasites, and potentially harmful white blood cells in donated blood components intended for transfusion. Major products include the INTERCEPT Blood System for platelets, plasma, and cryoprecipitation, with the red blood cell system in development. The company is also developing a blood system for red blood cells. Cerus serves blood centers, hospitals, and patients who require safe blood transfusions. The company utilizes a direct sales force and distributors to market its products in the Americas, Europe, the Middle East, and Latin America. Cerus is headquartered in Concord, California, the US.
Headquarters
United States of America
Address
1220 Concord Avenue, California, 94520
Website
www.cerus.com
Telephone
1 925 2886000
No of Employees
275
Industry
Medical Equipment
Ticker Symbol & Exchange
CERS (NASD)
Revenue (2024)
$233.8M
16.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
25.3%
(2024 vs 2023)
Market Cap*
$585.1M
Net Profit Margin (2024)
XYZ
35.7%
(2024 vs 2023)
* As of and is in US$
Cerus Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Blood System for Platelets | Intercept |
| Blood System for Plasma | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In May, the company received regulatory approval for its INT200, the Next-Generation INTERCEPT Illumination Device, from the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). |
| 2025 | Regulatory Approval | In March, the company secured CE mark approval for its INT200 LED device, enabling commercialization across the EU under MDR. |
| 2024 | Regulatory Approval | In March, the company received approval from the US Food and Drug Administration (FDA) for its extended shelf life for INTERCEPT platelet processing sets. |
Competitor Comparison
| Key Parameters | Cerus Corp | Grifols SA | Octapharma AG | Kedrion Biopharma Inc | MacoPharma International Gmbh |
|---|---|---|---|---|---|
| Headquarters | United States of America | Spain | Switzerland | United States of America | Germany |
| City | Concord | Sant Cugat Del Valles | Lachen | Fort Lee | Langen |
| State/Province | California | Barcelona | Schwyz | New Jersey | Hessen |
| No. of Employees | 275 | 23,822 | 11,141 | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William M. Greenman | Chairman | Executive Board | 2011 | 59 |
| Vivek K. Jayaraman | President; Chief Executive Officer; Director | Executive Board | 2026 | 51 |
| Kevin D. Green | Chief Financial Officer; Vice President - Finance | Senior Management | 2013 | 54 |
| Chrystal Jensen | General Counsel; Chief Legal Officer | Senior Management | 2012 | 55 |
| Richard J. Benjamin Ph.D | Chief Medical Officer | Senior Management | 2015 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer